Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
For the first time, researchers safely and effectively treated cells and mice with ovarian cancer using the CRISPR-Cas9 gene-editing tool plus ... Read more
When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) ... Read more
The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening ... Read more
Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes ... Read more
A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes ... Read more
Using standard platinum-based chemotherapy is often associated with the formation of unfavorable treatment-resistant cancer stem cells, which may ultimately contribute to ... Read more
A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian ... Read more
